A potential treatment using this TDP-43’s gain-of-function targeting approach might need to be combined with drugs that target its loss-of-function, and potentially with drugs focused on different targets, such as autophagy.77 Currently, it seems we are on the edge of a new era for the developing of treatments for neurodegenerative diseases such as ALS and FTD. Here, TARDBP is linked to frontotemporal dementia.